The DOI matches its Crossref record.
Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154.
Abstract
Clinical islet cell transplantation has resulted in insulin independence in a limited number of cases. Rejection, recurrence of autoimmunity, and impairment of normal islet function by conventional immunosuppressive drugs, e.g., steroids, tacrolimus, and cyclosporin A, may all contribute to islet allograft loss. Furthermore, intraportal infusion of allogeneic islets results in the activation of intrahepatic macrophages and endothelial cells, followed by production of proinflammatory mediators that can contribute to islet primary nonfunction. We reasoned that the beneficial effects of anti-CD154 treatment on autoimmunity, alloreactivity, and proinflammatory events mediated by macrophages and endothelial cells made it an ideal agent for the prevention of islet allograft failure. In this study, a nonhuman primate model (Papio hamadryas) was used to assess the effect of humanized anti-CD154 (hu5c8) on allogeneic islet engraftment and function. Nonimmunosuppressed and tacrolimus-treated recipients were insulin independent posttransplant, but rejected their islet allografts in 8 days. Engraftment and insulin independence were achieved in seven of seven baboon recipients of anti-CD154 induction therapy administered on days -1, 3, and 10 relative to the islet transplant. Three of three baboons treated with 20 mg/kg anti-CD154 induction therapy experienced delayed rejection episodes, first detected by elevations in postprandial blood glucose levels, on postoperative day (POD) 31 for one and on POD 58 for the other two. Re-treatment with three doses of anti-CD154 resulted in reversal of rejection in all three animals and in a return to normoglycemia and insulin independence in two of three baboons. It was possible to reverse multiple episodes of rejection with this approach. A loss of functional islet mass, as detected by reduced first-phase insulin release in response to intravenous glucose tolerance testing, was observed after each episode of rejection. One of two baboons treated with 10 mg/kg induction therapy became insulin independent post-transplant but rejected the islet graft on POD 10; the other animal experienced a reversible rejection episode on POD 58 and remained insulin independent and normoglycemic until POD 264. Two additional baboon recipients of allogeneic islets and donor bone marrow (infused on PODs 5 and 11) were treated with induction therapy (PODs -1, 3, 10), followed by initiation of monthly maintenance therapy (for a period of 6 months) on POD 28. Rejection-free graft survival and insulin independence was maintained for 114 and 238 days, with preservation of functional islet mass observed in the absence of rejection. Prevention and reversal of rejection, in the absence of the deleterious effects associated with the use of conventional immunosuppressive drugs, make anti-CD154 a unique agent for further study in islet cell transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A. M., & Adorini, L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.1945 · Cited by 617
Islet Transplantation as a Treatment for Diabetes — A Work in Progress
Robertson, R. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032425 · Cited by 434
Kenyon, N. S., Chatzipetrou, M., Masetti, M., Ranuncoli, A., Oliveira, M., Wagner, J. L., Kirk, A. D., Harlan, D. M., Burkly, L. C., & Ricordi, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8132 · Cited by 415
Self-citationClinical islet transplantation: advances and immunological challenges
Ricordi, C., & Strom, T. B. (2004) · Nature Reviews Immunology · doi:10.1038/nri1332 · Cited by 368
Self-citation
Metadata
- Authors
- Kenyon, N. S., Fernandez, L. A., Lehmann, R., Masetti, M., Ranuncoli, A., Chatzipetrou, M., Iaria, G., Han, D., Wagner, J. L., Ruiz, P., Berho, M., Inverardi, L., Alejandro, R., Mintz, D. H., Kirk, A. D., Harlan, D. M., Burkly, L. C., & Ricordi, C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1999-07-01
- Volume
- 48
- Issue
- 7
- Pages
- 1473-1481
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2125797482
- Cited by
- 207
- References
- 0
- FWCI
- 19.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. https://app.cochat.ai/papers/10.2337/diabetes.48.7.1473
- The paper
- Kenyon, N. S., Fernandez, L. A., Lehmann, R., Masetti, M., Ranuncoli, A., Chatzipetrou, M., Iaria, G., Han, D., Wagner, J. L., Ruiz, P., Berho, M., Inverardi, L., Alejandro, R., Mintz, D. H., Kirk, A. D., Harlan, D. M., Burkly, L. C., & Ricordi, C. (1999). Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes. https://doi.org/10.2337/diabetes.48.7.1473
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.